Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Sep 1;20(17):4422-4.
doi: 10.1158/1078-0432.CCR-14-0932. Epub 2014 Jul 24.

"Companion diagnostics": has their time come and gone?

Fred R Hirsch  1 , Paul A Bunn Jr  2 , Roy S Herbst  3
Affiliations
Comment

"Companion diagnostics": has their time come and gone?

Fred R Hirsch et al. Clin Cancer Res. .

Abstract

Rapid development of molecularly targeted drugs requires a "companion diagnostic" that could delay drug development and limit availability of active drugs for relevant patients. Were the negative results from MetMab studies in patients with advanced non-small cell lung cancer due to drug failure or failure of the right companion diagnostic?

PubMed Disclaimer

Comment on

References

    1. Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, et al. Biomarker Analysis from a Placebo-Controlled Phase II Study Evaluating Erlotinib+/- Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit. Clin Cancer Res. 2014 doi: 10.1158/1078-0432.CCR-13-1836. - PMC - PubMed
    1. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Jr, Blumenschein JR, et al. Randomized Phase II Trial of Ornatuzumab in Combination With Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer. J Clin Oncol. 2013;31(32):4105–14. - PMC - PubMed
    1. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353(2):123–32. - PubMed
    1. Engelman JA, Janne PA. Mechanisms of acquired Resistance to epidernmal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008;14(10):2895–9. - PubMed
    1. Spiegel DR, Edelman MJ, O’Byrne K, Paz-Ares L, Shames D, Yu W, et al. Ornatuzumab plus Erlotinib versus erlotinib in previously treated stage IIIb and IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM 4971g) global study. Proc Am Soc Clin Oncol Annual Meeting. 2014 abstract # 8000.

Publication types

MeSH terms